A Randomised, Crossover, Double-blind, Placebo-Controlled study to evaluate the Pharmacodynamics of single oral dose of NDI-010976 (GS-0976) in healthy Obese subjects

Trial Profile

A Randomised, Crossover, Double-blind, Placebo-Controlled study to evaluate the Pharmacodynamics of single oral dose of NDI-010976 (GS-0976) in healthy Obese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs GS 0976 (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Oct 2017 Results assessing de novo lipogenesis and fatty acid oxidation as potential pharmacodynamic biomarkers of GS-0976 activity (n=10), presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 21 Sep 2017 New trial record
    • 01 Aug 2017 Results published in the Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top